Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This study investigates the safety/toxicity and potential anti-tumor activity of sequential
administration of nivolumab and escalating doses of the mTOR inhibitor ABI-009 in advanced
Ewing's sarcoma, PEComa, epithelioid sarcoma, desmoid tumor, chordoma, non-small cell lung
cancer, small cell lung cancer, urethelial carcinoma, melanoma, renal cell carcinoma,
squamous cell carcinoma of head and neck, hepatocellular carcinoma, classical Hodgkin's
lymphoma, MSI-H/dMMR metastatic colorectal cancer, and tumors with genetic mutations
sensitive to mTOR inhibitors